TAVR在美国严重症状性主动脉狭窄患者中的成本效用和成本效益分析数据集

数据集获取（Figshare）

• 源站标题：Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population
• DOI：10.6084/m9.figshare.20517323.v2
• 发布日期：2022-08-26
• 文件数：1342 个
• 文件总体积：2.23 GB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-utility_and_cost-benefit_analysis_of_TAVR_availability_in_the_US_severe_symptomatic_aortic_stenosis_patient_population/20517323

命令行下载

curl -L -o "0. ACS_2017_median_age.do" "https://ndownloader.figshare.com/files/36853688"
curl -L -o "0. ACS_2017_median_age.log" "https://ndownloader.figshare.com/files/36853691"
curl -L -o "0. USlifetable2017.do" "https://ndownloader.figshare.com/files/36853694"
curl -L -o "0. USlifetable2017.log" "https://ndownloader.figshare.com/files/36853697"
curl -L -o "01hr12A.pdf" "https://ndownloader.figshare.com/files/36853700"
curl -L -o "01hr14A.pdf" "https://ndownloader.figshare.com/files/36853703"
curl -L -o "01hr16A.pdf" "https://ndownloader.figshare.com/files/36853706"
curl -L -o "02hr12B.pdf" "https://ndownloader.figshare.com/files/36853709"

文件清单

• 0. ACS_2017_median_age.do（904 B）
• 0. ACS_2017_median_age.log（7.22 KB）
• 0. USlifetable2017.do（3.39 KB）
• 0. USlifetable2017.log（6.22 KB）
• 01hr12A.pdf（414.73 KB）
• 01hr14A.pdf（481.12 KB）
• 01hr16A.pdf（481.82 KB）
• 02hr12B.pdf（648.03 KB）
• 02hr14B.pdf（617.49 KB）
• 02hr16B.pdf（206.16 KB）
• 03hr12C.pdf（1.16 MB）
• 03hr14C.pdf（1.07 MB）
• 03hr16C.pdf（379.52 KB）
• 04hr14D.pdf（459.22 KB）
• 04hr16D.pdf（395.86 KB）
• 05hr12D.pdf（361.41 KB）
• 05hr14E.pdf（260.74 KB）
• 05hr16E.pdf（266.62 KB）
• 06hr12E.pdf（248.81 KB）
• 06hr14F.pdf（311.24 KB）

文件总体积 2.23 GB（源站 API 实测）。

数据说明

We evaluated the availability of transcatheter aortic valve replacement (TAVR) to determine its value across all severe symptomatic aortic stenosis (SSAS) patients, especially those untreated because of concerns regarding invasive surgical AVR (SAVR) and its impact on active aging.
We performed payer perspective cost-utility analysis (CUA) and societal perspective cost-benefit analysis (CBA). The CBA’s benefit measure is active time: salaried labor, unpaid work, and active leisure. The study population is a cohort of US elderly SSAS patients. We compared a “TAVR available” scenario in which SSAS patients distribute themselves across TAVR, SAVR, and medical management (MM); and a “TAVR not available” scenario with only SAVR and MM. We structured each scenario with a decision-tree model of SSAS patient treatment allocation. We measured the association between health and active time in the US Health and Retirement Study and used this association to impute active time to SSAS patients given their health.
The incremental cost-effectiveness ratio (ICER) and rate of return (RoR) of TAVR availability were $8,533 and 395%, respectively. CUA net monetary benefits (NMB) were $212,199 per patient and $43.4 billion population-wide. CBA NMB were $50,530 per patient and $10.3 billion population-wide.
Among study limitations were scarcity of evidence regarding key parameters and the lack of long-term survival, health utility, and treatment cost data. Our analysis did not account for TAVR durability, retreatments, and valve-in-valve treatments.
Across risk-, age-, and treatment-eligibility groups, TAVR is the economically optimal treatment choice. It represents strong value-for-money per patient and population-wide. The vast majority of TAVR value involves raising treatment uptake among the untreated.
Aortic stenosis (AS) is a common and lethal heart disease. Surgical treatment has long been available, but its invasiveness limits uptake. More recently, transcatheter aortic valve replacement (TAVR) has emerged as a treatment alternative. Its minimal invasiveness has significantly increased treatment rates, but economic evaluations omit this benefit, risking undervaluation. W

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.20517323.v2（source: https://tandf.figshare.com/articles/dataset/Cost-utility_and_cost-benefit_analysis_of_TAVR_availability_in_the_US_severe_symptomatic_aortic_stenosis_patient_population/20517323）。